REGENXBIO Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
RGNX$8.07+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page | ||
|---|---|---|
| Part I | ||
| Information Regarding Forward-Looking Statements | 1 | |
| Industry and Market Data | 2 | |
| Item 1. | Business | 2 |
| Item 1A. | Risk Factors | 29 |
| Item 1B. | Unresolved Staff Comments | 62 |
| Item 1C. | Cybersecurity | 62 |
| Item 2. | Properties | 63 |
| Item 3. | Legal Proceedings | 63 |
| Item 4. | Mine Safety Disclosures | 63 |
| Part II | ||
| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 64 |
| Item 6. | Reserved | 65 |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 66 |
| Item 7A. | Quantitative and Qualitative Disclosures about Market Risk | 80 |
| Item 8. | Financial Statements and Supplementary Data | 80 |
| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 80 |
| Item 9A. | Controls and Procedures | 80 |
| Item 9B. | Other Information | 82 |
| Item 9C. | Disclosure Regarding Foreign Jurisdictions That Prevent Inspections | 82 |
| Part III | ||
| Item 10. | Directors, Executive Officers and Corporate Governance | 83 |
| Item 11. | Executive Compensation | 83 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 83 |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence | 83 |
| Item 14. | Principal Accountant Fees and Services | 83 |
| Part IV | ||
| Item 15. | Exhibits, Financial Statement Schedules | 84 |
| Index to Consolidated Financial Statements | 85 | |
| Exhibit Index | 124 | |
| Signatures | 127 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.